The first liquid free and silicone gel free breast implants.
ImpLite is introducing three new implants that will address this large market as follows:
a. The Freedom™ implant market > 1,350,000 cases a year/WW valued at $2.1B PLUS an existing pool of women that have undergone breast surgery with implants in the past estimated at 5,500,000 cases. Past-surgery market (patients who were operated on in the past) is valued at $15B.
b. The Magic™ implant is a completely new device offering projection-only solution to women with ample breast tissue and ptotic breasts. We project that the worldwide market can grow to 100,000 and 200,000 in the second and third years of sales and valued at $150 million and $300 million respectively. Growth is expected to be exponential thereafter.
c. The Essential™ implant market is about 850,000 annual cases out of the 1.7 million new cases of breast cancer worldwide. The market for immediate reconstruction is valued at $680,000. The market for delayed reconstruction reflecting past 10 years is valued at $2.0B.
Three novel lines of 'dry' (non-liquid filling) and very light breast implants (1/4 of current implants) superior to current implants:
i. The Freedom™ implant designed to replace gel & saline filled implants that have to be replaced as mandated by FDA every 10 years; it is similar in shape but weighs 1/3 of a gel implant and is safe of leakage, shell rupture and will last longer.
ii. The Magic™ implant by offering projection-only solution (40gm) for women with breast ptosis without adding weight and volume to the breast thus revolutionizing the aesthetic breast surgery market.
iii. The Essential™ implant is the first ever implant designed for immediate reconstruction for lumpectomy (partial breast excision for cancer) and delayed reconstruction available in various shapes and volumes (to match cancer size).
The three new product lines are offering superior new solutions in every aspect of breast surgery for aesthetic surgeons and for breast oncologic surgeons. By having the three distinct products, ImpLite can benefit from the private, out-of-pocket aesthetic market as well as the reimbursed market of cancer patients.
The devices design and manufacturing technologies are protected by 7 patent applications and granted patents.